CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 245 enrolled
Drug / intervention
STOPCOVother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05119348
NCT05119348N/ACompleted

Transmission of COVID19 in Crowded Environments

Desmond Tutu HIV Foundation·interventional·Posted Nov 15, 2021·Updated Aug 9, 2024

In Brief

A clinical study evaluating STOPCOV for Covid19 and Sars-CoV-2 Infection. Completed, enrolled 245 participants across 1 site.

Detailed Summary

South Africa recorded it's first coronavirus disease 2019 (COVID19) case on March 5, 2020. In response to the COVID19 outbreak World Health Organisation recommendations, South Africa implemented non-pharmaceutical recommendations. The major risk mitigation factors recommended by World Health Organisation and others - physical distancing and hygiene - are extremely difficult to implement in much of Africa. The investigators will conduct a randomised controlled trial to investigate the effect of an infection mitigation intervention to assess the effect on household transmission of severe acute respiratory syndrome (SARS) coronavirus (CoV) 2 in household settings with an index patient diagnosed SARS-CoV-2 positive.

Study Details

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedNov 15, 2021
Enrollment StartSep 14, 2020
Primary CompletionAug 4, 2021
Study CompletionOct 21, 2021
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 4.6 years ago

Interventions

STOPCOVother

Fieldworkers delivered an infection mitigation intervention which consisted of personal protective equipment and messaging on managing COVID19 and reducing onward transmission of SARS-CoV-2 infection.